Stockreport

Relmada Therapeutics GAAP EPS of -$0.27 misses by $0.13 [Seeking Alpha]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Research and development expense for the three months ended December 31, 2025, totaled $8.1 million, compared to $11.0 million for the three months ended December 31, 2 [Read more]